SITC 30th Anniversary Annual Meeting

The SITC 2015 Presentation Archive is supported through a generous contribution from AstraZeneca/MedImmune.

Access slide decks and video via the links in the schedule below.

PDF = PDF of slides is available

= Presentation video is available

Program Schedule

Friday, November 6, 2015

7:00 – 7:45 a.m.	State of SITC: Membership Business Meeting
7:45 – 7:50 a.m.	Presidential Welcome Howard L. Kaufman, MD, FACS – Rutgers Cancer Institute of New Jersey
Milestones in Immunotherapy
Non-CME Session
7:50 – 8:20 a.m.	Targeting Immune Checkpoints in Cancer Therapy: New Insights, Opportunities and Prospects for a Cure James P. Allison, PhD – University of Texas MD Anderson Cancer Center
8:20 – 8:50 a.m.	From Immune Surveillance to Personalized Cancer Vaccines Robert Schreiber, PhD – Washington University School of Medicine
8:50 – 9:20 a.m.	Therapeutic Cancer Vaccines Cornelis J.M. Melief, MD, PhD – Leiden University Medical Center
9:20 – 9:50 a.m.	Curative Potential of Cell Transfer Therapy for Cancer Steven A. Rosenberg, MD, PhD – National Cancer Institute, National Institutes of Health
9:50 – 9:55 a.m.	Questions and Answers
9:55 – 10:15 a.m.	Break

New Insights into T Cell Function 1.75 AMA PRA Category 1 Credits™
Co-Chairs: Rafi Ahmed, PhD – Emory University Pamela S. Ohashi, PhD – Princess Margaret Cancer Centre
10:15 – 10:20 a.m.	Introduction Pamela S. Ohashi, PhD – Princess Margaret Cancer Centre
10:20 – 10:40 a.m.	Building Curative Anti-tumor T cells Nicholas P. Restifo, MD – National Cancer Institute
10:40 – 11 a.m.	Tissue Resident Memory T Cells David Masopust, PhD – University of Minnesota
11 – 11:20 a.m.	T Cell Exhaustion Rafi Ahmed, PhD – Emory University
11:20 – 11:40 a.m.	New Insights into CD8 Function and Regulation Pamela S. Ohashi, PhD – Princess Margaret Cancer Centre
11:40 – 11:55 p.m.	Tissue Resident Memory T Cells Create Genetically Distinct Immune Microenvironment within Melanoma Metastasis Kavita Dhodapkar, MD – Yale University
11:55 – Noon	Closing Remarks Rafi Ahmed, PhD – Emory University

Late Breaking Abstract Session I Non-CME Session
Noon – 12:15 p.m.	Preliminary Results from a PhaseI/II Study of Epacadostat (incb024360) in Combination with Pembrolizumab in Patients with Selected Advanced Cancers Tara C. Gangadhar, MD – Abramson Cancer Center of the University of Pennsylvania
12:15 – 12:30 p.m.	The PTEN Pathway in Tregs Fuctions as a Critical Driver of the Immunosuppressive Tumor Microenvironment and Tolerance to Apoptotic Cells David H. Munn, MD – Georgia Regents University Cancer Center
12:30 – 12:45 p.m.	Tumor Response from Durvalumab (MED14736) + Tremelimumab Treatment in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) is Observed Regardless of PD-L1 Status Naiyer A. Rizvi, MD – Columbia University Medical Center
12:45 – 2 p.m.	Lunch and Poster Viewing

Smalley Keynote .5 AMA PRA Category 1 Credits™
2 – 2:05 p.m.	Introduction Howard L. Kaufman, MD, FACS – Rutgers Cancer Institute of New Jersey
2:05 – 2:30 p.m.	Smalley Keynote Presentation Tasuku Honjo, MD, PhD – Deparment of Immunology and Genomic Medicine, Graduate School of Medicine, Kyoto University
2:30 – 2:35 p.m.	Question & Answer Tasuku Honjo, MD, PhD – Department of Immunology and Genomic Medicine, Graduate School of Medicine, Kyoto University
Adoptive Immunotherapy Developed in Collaboration with International Society for Cell Therapy (ISCT) 1.75 AMA PRA Category 1 Credits™
Co-Chairs: Malcolm K. Brenner, MD, PhD – Baylor College of Medicine Bruce Levine, PhD – Abramson Cancer Center, University of Pennsylvania
2:35 – 2:55 p.m.	Enhancing CAR T Cell Activity via the TCR Cliona M. Rooney, PhD – Baylor College of Medicine
2:55 – 3:15 p.m.	Functional Determinants of Highly Active Cell Therapy Stephen Grupp, MD, PhD – University of Pennsylvania
3:15 – 3:35 p.m.	Regulatory T Cells to Induce Tolerance in Hematopoletic Stem Cell Transplantation Bruce R. Blazar, MD – University of Minnesota
3:35 – 3:50 p.m.	Durable Complete Response in a Patient with Metastatic Melanoma Following Adoptive Transfer of Autologous T Cells Recognizing 10 Mutated Tumor Antigens Todd Prickett, PhD – National Cancer Institute/National Institutes of Health
3:50 – 4:05 p.m.	A Bispecific Chimeric Antigen Receptor Molecule Enhances T Cell Activation Through Dual Immunological Synapse Formation and Offsets Antigen Escape in Glioblastoma Nabil Ahmed, MD – Baylor College of Medicine
4:05 – 4:20 p.m.	Panel Discussion
4:20 – 4:50 p.m.	Break

Concurrent Session: Immunogenomics and Oncogenetics 1.5 AMA PRA Category 1 Credits™
Co-Chairs: Francesco M. Marincola, MD – Sidra Medical and Research Center Kai Wucherpfennig, MD, PhD – Harvard Medical School
4:50 – 4:55 p.m.	Introduction Francesco M. Marincola, MD – Sidra Medical and Research Center
4:55 – 5:10 p.m.	Discovery and Characterization of an Immunogenic Neoantigen in a Patient with Metastatic Triple Negative Breast Cancer Yasmine Assadipour, MD – National Insitutes of Health
5:10 – 5:25 p.m.	In Vivo Discovery of Novel Targets for Cancer Immunotherapy Kai Wucherpfennig, MD, PhD – Harvard Medical School
5:25 – 5:40 p.m.	Understanding the CD8T Cell Response to Melanoma Using Transnuclear Mouse Models Stephanie Dougan, PhD – Dana-Farber Cancer Institute
5:40 – 5:55 p.m.	Toward the Identification of Genetic Determinants of Cancer Immune Responsiveness Davide Bedognetti, MD, PhD – Sidra Medical and Research Center
5:55 – 6:10 p.m.	From Immunogenetic Polymorphism to Functional Antitumor Lymphocyte Mitochondrial Dynamics Anil Shanker, PhD – Meharry Medical College School of Medicine/Vanderbilt-Ingram Cancer Center
6:10 – 6:15 p.m.	Closing Kai W. Wucherpfenning, MD, PhD – Harvard Medical School

Concurrent Session: Cutting-Edge Clinical Trials 1.5 AMA PRA Category 1 Credits™
Co-Chairs: Sandra Demaria, MD – New York University School of Medicine Elizabeth M. Jaffee, MD – Johns Hopkins University
4:50 – 4:55 p.m.	Introduction Sandra Demaria, MD – Weill Cornell Medical College
4:55 – 5:15 p.m.	PD1 Modulation in Mismatch Repair Deficient Tumors Dung T. Le, MD – The Sidney Kimmel Comprehensive Cancer Center at John Hopkins University
5:15 – 5:35 p.m.	Targetable Immune Escape Mechanisms in Hodkins' Lymphoma Margaret A. Shipp, MD – Dana-Farber Cancer Institute
5:35 – 5:55 p.m.	Radiotherapy as Adjuvant to Immunotherapy: Clincal Translation Silvia Formenti, MD – New York Presbyterian/Weill Cornell Medical Center
5:55 – 6:10 p.m.	Autologous HER2 CMV Bispecific CAR T Cells are Safe and Demonstrate Clincal Benefit for Glioblastoma in a Phase I Trial Nabil Ahmed, MD – Baylor College of Medicine
6:10 – 6:15 p.m.	Closing Elizabeth M. Jaffee, MD – The Sidney Kimmel Comprehensive Cancer Center at John Hopkins University

Saturday, November 7, 2015
Cancer Immunotherapy Trials Network Update .75 AMA PRA Category 1 Credits™
7:45 – 8:35 a.m.	Martin Cheever, MD – Fred Hutchinson Cancer Research Center

Coinhibition & Costimulation 1.75 AMA PRA Category 1 Credits™
Co-Chairs: Andrew D. Weinberg, PhD – Earle A. Chiles Research Institute, Providence Medical Center Jedd D. Wolchok, MD, PhD – Memorial Sloan Kettering Cancer Center
8:35 – 8:40 a.m.	Introduction Andrew D. Weinberg, PhD – Earle A. Chiles Research Institute, Providence Medical Center
8:40 – 9:05 a.m.	Combined Coinhibition in the Clinic Jedd D. Wolchok, MD, PhD – Memorial Sloan Kettering Cancer Center
9:05 – 9:30 a.m.	Preclinical/Costimulation within Tumor Immunotherapy Isabelle Le Mercier, PhD – Geisel School of Medicine at Dartmouth
9:30 – 9:50 a.m.	OX40 Agonist Agents in Pre-clinical Models Daniel Hirschhorn-Cymerman, PhD – Memorial Sloan Kettering Cancer Center
9:50 – 10:05 a.m.	Agonist Anti-4-1 BB Plus Neutralizing Anti-CTLA-4 or –PD-L1 Synergize to Promote Tumor Regression by Rescuing Dying Dysfunctional CD8+ T Cells Within the Tumor Microenvironment Brendan Horton, MD, PhD – University of Chicago
10:05 – 10:20 a.m.	PD-1 Blockade Upregulate Tim-3 Expression as a Compensatory Regulation of Immune Check Point Receptors in HNSCC TIL Gulidana Shayan – University of Pittsburgh
10:20 – 10:35 a.m.	Break

Mechanisms and Responses to Immune Therapy 1.5 AMA PRA Category 1 Credits™
Co-Chairs: Thomas F. Gajewski, MD, PhD – University of Chicago Jennifer A. Wargo, MD, MMSc – University of Texas MD Anderson Cancer Center
10:35 – 10:40 a.m.	Introduction Thomas Gajewski, MD, PhD – University of Chicago
10:40 – 11 a.m.	Antigen Identification from Patients Responding to Immunotherapy Paul F. Robbins, PhD – National Cancer Institute/National Institutes of Health
11 – 11:20 a.m.	Understanding Responses to Therapy: the Tissue is the Issue Jennifer A. Wargo, MD, MMSc – University of Texas MD Anderson Cancer Center
11:20 – 11:40 a.m.	Molecular Determinants of the Host Immune Response to Cancer Thomas F. Gajewski, MD, PhD – University of Chicago
11:40 – 11:55 a.m.	Characterization of Oncogenic Pathways Linked with T Cell Exclusion in Urothelial Bladder Cancer Randy Sweis, MD – University of Chicago
11:55 – Noon	Closing Jennifer A. Wargo, MD, MMSc – University of Texas MD Anderson Cancer Center

Late Breaking Abstract Session II
Non-CME Session
Noon – 12:15 p.m.	Interim Results of an Ongoing Phase I, Dose Escalation Study of MGA271 (Fc-Optimized Humanized Anti-B7-H3 Monoclonal Antibody) in Patients with Refractory B7-H-3-Expressing Neoplasms or Neoplasms whose Vasculature Expresses B7-H3 John D. Powderly II, MD, CD1 – Carolina BioOncology Institute, PLLC
12:15 – 12:30 p.m.	Treatment of Leukemia Antigen-Loss Relapses Occurring after CD19-targeted Immunotherapies by Combination of Anti-CD123 and Anti-CD19 Chimeric Antigen Receptor T Cells Marco Ruella, MD – University of Pennsylvania
12:30 – 12:45 p.m.	Efficacy of Anti-ICOS Agonist Monoclonal Antibodies in Preclinical Tumor Models Provides a Rationale for Clinical Development as Cancer Immunotherapeutics Michael J. Briskin, PhD – Jounce Therapeutics
12:45 – 2 p.m.	Lunch and Poster Viewing

Presidential Session 1.0 AMA PRA Category 1 Credits™
Chair Howard L. Kaufman, MD, FACS – Rutgers Cancer Institute of New Jersey
2 – 2:05 p.m.	Introduction Howard L. Kaufman, MD, FACS – Rutgers Cancer Institute of New Jersey
2:05 – 2:20 p.m.	Inhibition of the T-Cell Oxygen Sensing Machinery Promotes Anti-Tumor Efficacy David Clever – National Cancer Institute/National Institute of Health – Surgery Branch
2:20 – 2:35 p.m.	Selection of Circulating PD-1 + Lymphocytes from Cancer Patients Enriches for Tumor-Reactive and Mutation- Specific Lymphocytes Alena Gros, PhD – National Cancer Institute/National Institute of Health – Surgery Branch
2:35 – 2:50 p.m.	Virus-Specific CD8+ T Cells Infiltrate Melanoma Lesions and Retain Function Despite High PD-1 Expression Dan Erkes – Thomas Jefferson University
2:50 – 3:05 p.m.	Inhibition of Fatty Acid Oxidation Modulates Immunosuppressive Functions of Myeloid-Derived Suppressor Cells and Enhances Cancer Therapies Amir Al-Khami, PhD – Louisiana State University Health Sciences Center

SITC Immunoscore Validation Project Update .25 AMA PRA Category 1 Credits™
3:05 – 3:20 p.m.	SITC Immunoscore Validation Project Update Bernard Fox, PhD – Earle A. Chiles Research Institute, Providence Cancer Center

SITC Biomarkers Task Force Update .25 AMA PRA Category 1 Credits™
3:20 – 3:35 p.m.	SITC Biomarkers Task Force Update Lisa H. Butterfield, PhD – University of Pittsburgh
3:35 – 4:05 p.m.	Break

Concurrent Session: Precision Immunology 1.5 AMA PRA Category 1 Credits™
Co-Chairs: Holden T. Maecker, PhD – Stanford University Medical Center Drew M. Pardoll, MD, PhD – Johns Hopkins University School of Medicine
4:05 – 4:10 p.m.	Introduction Holden T. Maecker, PhD – Stanford Univeristy
4:10 – 4:35 p.m.	Pre-existing Immunity and Treatment Outcome with Anti-PD1 Therapy in Melanoma Paul Tumeh, MD – University of California Los Angeles
4:35 – 4:55 p.m.	Epitope Signatures and Melanoma Response to CTLA4 Therapy Timothy Chan, MD, PhD – Memorial Sloan Kettering Cancer Center
4:55 – 5:15 p.m.	PD-1 Blockade in Mismatch Repair Deficient Tumors Luis A. Diaz, MD – Johns Hopkins Sidney Kimmel Cancer Center
5:15 – 5:30 p.m.	Dissecting the Tumor Micro-Environment in Triple Negative Breast Cancer Identifies a Mutually Exclusive Expression Pattern of the Immune Co-Inhibitory Molecules B7-H4 and PD-L1 Kurt Schalper, MD, PhD – Yale University

Concurrent Session: Innate Immunity 1.5 AMA PRA Category 1 Credits™
Co-Chairs: Vincenzo Bronte, MD – University of Verona Keith L. Knutson, PhD – Mayo Clinic Jacksonville
4:05 – 4:10 p.m.	Introduction Keith L. Knutson, PhD – Mayo Clinic Jacksonville
4:10 – 4:35 p.m.	PTX3 as an Extrinsic Oncosuppressor Regulating Complement and Macrophage Driven Inflammation Mantovani Alberto, MD – Humanitas University
4:35 – 5 p.m.	Chimeric Endocrine Receptor-Expressing T cells Influenced by the Microbiodata Delay Ovarian Cancer Progression by Boosting Pre-Existing Anti-Tumor Immunity Jose R. Conejo-Garcia, MD, PhD – The Wistar Institute
5 – 5:15 p.m.	Targeting KIT on Innate Immune Cells Enhances the Antitumor Activity of Checkpoint Inhibitors in Vivo Joseph McLaughlin, MD – Yale New Haven Hospital Smilow Cancer Center
5:15 – 5:30 p.m.	Local Immunotherapy with ONCOS-102 Shapes Harmful Tumor Associated CD68+ Macrophages to Become Beneficial Cells that Correlate with Increased Overall Survival Dmitriy Zamarin, MD, PhD – Memorial Sloan Kettering Cancer Center

Sunday, November 8, 2015
Hot Topic Session on the Value of Cancer Immunotherapy Non-CME Session Chair: Howard L. Kaufmann, MD, FACS – Rutgers Cancer Institue of New Jersey
7:45 – 7:50 a.m.	Welcome and Introductions Howard L. Kaufman, MD, FACS – Rutgers Cancer Institute of New Jersey
7:50 – 8 a.m.	Perspective Biomarkers Lisa H. Butterfield, PhD – University of Pittsburgh
8 – 8:15 a.m.	Value: "Real World" Points William McGivney, PhD
8:15 – 8:20 a.m.	Perspective: Analytics/Immunotherapy Kimberly A Shafer-Weaver, PhD – AstraZeneca
8:20 – 8:25 a.m.	Perspective: Industry Kevin Trapp – Bristol-Myers Squibb
8:25 – 8:30 a.m.	Perspective: Patient Support Gwen Darien – Cancer Support Community
8:30 – 8:35 a.m.	Panel Discussion
8:35 – 9:15 a.m.	Audience Questions & Answer Moderator: Peter P. Yu, MD, FACP, FASCO – Palo Alto Medical Foundation

Save the Date!

Save the dates for SITC 2016!
November 9 – 13, 2016
Gaylord National Hotel & Convention Center, National Harbor, Maryland

Thank You, Supporters!

Thank you, SITC 2015 supporters. Because of your generosity, SITC 2015 was a great success!

Interested in supporting other SITC programs? Confirm your support today!

SITC 30th Anniversary Annual Meeting

Program Schedule

Friday, November 6, 2015

Milestones in Immunotherapy

New Insights into T Cell Function

Late Breaking Abstract Session I

Smalley Keynote

Adoptive Immunotherapy

Concurrent Session: Immunogenomics and Oncogenetics

Concurrent Session: Cutting-Edge Clinical Trials

Saturday, November 7, 2015

Cancer Immunotherapy Trials Network Update

Coinhibition & Costimulation

Mechanisms and Responses to Immune Therapy

Late Breaking Abstract Session II

Presidential Session

SITC Immunoscore Validation Project Update

SITC Biomarkers Task Force Update

Concurrent Session: Precision Immunology

Concurrent Session: Innate Immunity

Sunday, November 8, 2015

Hot Topic Session on the Value of Cancer Immunotherapy

Save the Date!

Thank You, Supporters!